A Segal analysis of medical cost trends for 2018 suggests that drug spending is still the major problem.
Read More
A report from Xcenda performs a site of care analysis for cancer treatment.
Read More
Research at JAMA Internal Medicine suggests that doctors who have a financial interest in imaging equipment and a history of low-value imaging, are most likely to do additional low-value imaging for low back and head pain.
http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2653911According to research published in the Journal of the American Medical Informatics Association, comparing online quality ratings of 78 doctors to more objective quality performance measures indicates that online reviews aren't worth much. This is likely because consumers rate quality on much they like a physician and other intangibles.
https://academic.oup.com/jamia/article-abstract/doi/10.1093/jamia/ocx083/4107665/Online-physician-ratings-fail-to-predict-actual?redirectedFrom=fulltextJP Morgan Chase issues a fact-filled report on consumer out-of-pocket spending on health care.
Read More
The Commonwealth Fund releases a brief describing certain employers' effort to manage high-cost patients.
Read More
Contrary to the most commonly cited cost, a new study at JAMA Internal Medicine finds that the cost of developing a cancer drug is around $650 million and that companies typically fully recover that cost within a couple of years after approval.
http://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2653012A paper from Stanford University researchers tests various models for improving prediction of who will be a high-cost patients.
Read More